



16<sup>th</sup> September, 2022

The Secretary  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

The Secretary,  
The National Stock Exchange of  
India Limited  
Exchange Plaza, 5th Floor  
Plot No. C/1, G Block  
Bandra-Kurla Complex  
Bandra East  
Mumbai 400 050

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure) Regulations (LODR) and Company's Policy of determination of Materiality of Events under Regulation 30 of LODR**

Dear Sirs/ Madam,

The Ministry of Health and Family Welfare, Government of India, has released the revised National List of Essential Medicines (NLEM), 2022. In the coming days, the National Pharmaceutical Pricing Authority (NPPA) will fix the ceiling price for the cost to patients of the products included in this revised list.

Since insulin glargine (100 IU/ ml) is now a part of the NLEM 2022 list, our Company's insulin glargine brand Lantus® will also be subject to price revision. The potential impact on the Company will be known only after the NPPA releases the prices. Though the price revision is likely to have an impact on sales, the Company does not expect a material impact on the profitability considering the arms-length operating model principle being followed with regard to sourcing of this product from Sanofi Group.

Given the current estimation of approximate 74 million people living with diabetes in India, our Company will continue to further sharpen its strategic focus on growth and expansion of the diabetes market segment, leveraging our entire portfolio of insulins.

Please take the above information on record.

Thanking you,

**For SANOFI INDIA LIMITED**

**RADHIKA SHAH  
COMPANY SECRETARY &  
COMPLIANCE OFFICER  
MEMBERSHIP NO. A19308**